News
-
-
-
-
PRESS RELEASE
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi gains EU approval for Cenrifki (tolebrutinib) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses, based on phase 3 studies. Cenrifki addresses SPMS disability progression -
-
-
-
-
-
PRESS RELEASE
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi's Tzield receives US FDA approval as first disease-modifying therapy for stage 3 type 1 diabetes, targeting autoimmune attack against insulin-producing beta cells
